Taurochenodeoxycholsäure
| Produktname | Taurochenodeoxycholsäure |
|---|---|
| CAS-Nummer | 516-35-8 |
| Molekülformel | C26H45NO6S |
| Molekulargewicht | 499.70 g/mol |
| Aussehen | Weißes bis cremefarbenes kristallines Pulver |
| Analyse (HPLC) | ≥98,01 TP3T |
| Löslichkeit | Soluble in water, methanol; slightly soluble in ethanol |
| Trocknungsverlust | ≤3.0% |
| Verbrennungsrückstand | ≤0,5% |
| Schwermetalle | ≤ 10 ppm |
| Lagerung | Store in a cool, dry place, protected from light |
Brauchst du Hilfe? Kontaktieren Sie unser Team

Synonyme: Taurochenodeoxycholic acid, TCDCA, 2-[(3α,5β,7α)-3,7-Dihydroxy-24-oxocholan-24-yl]aminoethanesulfonic acid, Chenodeoxycholyltaurine, Taurochenodeoxycholate
Taurochenodeoxycholic acid (TCDCA) is a taurine-conjugated bile acid that occurs naturally in the bile of humans and other mammals. It is one of the primary bile salts, synthesized in the liver from chenodeoxycholic acid and taurine. This conjugation significantly increases its water solubility and reduces its cytotoxicity compared to unconjugated bile acids. TCDCA plays a critical role in lipid digestion and absorption, and has emerged as a molecule of interest in pharmaceutical and metabolic research.
As a bile acid derivative, TCDCA is structurally characterized by a steroid nucleus with hydroxyl groups at the 3α and 7α positions, and a side chain ending in a taurine moiety. This amphipathic structure allows it to act as a detergent, forming mixed micelles that facilitate the emulsification of dietary fats and fat-soluble vitamins. Its physiological importance extends beyond digestion; TCDCA is a signaling molecule that activates nuclear receptors such as FXR and TGR5, influencing glucose and lipid metabolism, energy homeostasis, and inflammation.
In the pharmaceutical industry, TCDCA is used as an intermediate in the synthesis of ursodeoxycholic acid (UDCA) and other bile acid-based drugs. It also serves as a reference standard for analytical methods and as a research tool in studies of bile acid metabolism, cholestasis, and liver diseases. Additionally, TCDCA has shown potential in drug delivery systems, particularly for enhancing the oral bioavailability of poorly soluble drugs through micellar solubilization.
LyvBio supplies high-purity Taurochenodeoxycholic acid with consistent quality, supported by comprehensive documentation. Our product is manufactured under strict quality control and is suitable for use as an API intermediate, reference standard, and research chemical.
| Parameter | Technische Daten |
|---|---|
| Analyse (HPLC) | ≥98,01 TP3T |
| Identification | IR, NMR conforms to structure |
| Trocknungsverlust | ≤3.0% |
| Verbrennungsrückstand | ≤0,5% |
| Schwermetalle | ≤ 10 ppm |
| Microbial Limits | Total aerobic count ≤1000 CFU/g; Yeast & Mold ≤100 CFU/g; E. coli absent |
Room,5-0203, Unit 5, Beiyuanmen Street,Xi'an,Shaanxi,China